From GlobeNewswire:

4D Molecular Therapeutics announced positive interim results from the Phase 2 PRISM trial evaluating intravitreal 4D-150 in severe wet AMD patients with high treatment burden. The high dose resulted in an 89% reduction in annual anti-VEGF injection rate, and 84% of patients received 0 or 1 injection, indicating potential for reducing treatment burden. The company plans to advance to Phase 3 trials and is hosting a webcast on February 5, 2024. Positive results show promise of 4D-150 as a safe, convenient, and transformational treatment for wet AMD patients, and may represent a significant advancement in the current treatment paradigm for these challenging cases. 4DMT is also evaluating 4D-150 in diabetic macular edema with encouraging Phase 2 results. A Phase 3 study is scheduled to compare 4D-150 with aflibercept, with an emphasis on reduced treatment burden and stable visual acuity. The company has completed enrollment and dosing in the Phase 2 SPECTRA Part 1 Dose Confirmation cohort for DME, with further milestones expected in 2024.



Read more: 4DMT Presents Positive Interim Data from Randomized Phase 2